Genomic Health Hopes to Net $43M in Stock Sale; Shares Climb 8 Percent | GenomeWeb
NEW YORK (GenomeWeb News) — Genomic Health today said it hopes to net around $43.3 million in a public stock offering.
 
News of the planned sale caused shares in the company to trade up 7.8 percent at $16.92 in afternoon trading on the Nasdaq exchange.
 
Genomic Health, which makes the Oncotype Dx breast cancer recurrence test, said it would use the cash to expand its marketing capabilities, fund R&D, and expand its lab operations.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.